Advance Tests, a leader in advanced diagnostics, is bringing a transformative solution to Alzheimer’s diagnosis in the UK with the exclusive launch of LucentAD Complete. Developed by Lucent Diagnostics, a brand of Quanterix Corporation, this innovative blood test combines multiple biomarkers, including p-Tau 217, to deliver highly accurate risk classification for amyloid pathology linked to Alzheimer’s Disease. Starting from 2 December 2024, the test will be accessible to UK patients and healthcare providers, offering a non-invasive and cost-effective alternative to traditional diagnostic methods. What Makes LucentAD Complete Unique? Early Booking Availability Patients and healthcare providers in the UK can now…
early detection
Luminous Global is launching its groundbreaking breast health monitoring device, the Luminous Pro Series, in the UK. This innovative tool is designed to empower women and men to take ownership of their breast health, offering a non-invasive, portable, and easy-to-use solution for early breast cancer detection. With breast cancer being the most common cancer in the UK, affecting 1 in 7 women in their lifetime, this launch promises to revolutionise breast health awareness and offer a game-changing approach to early detection. Revolutionary Technology for Early Detection The Luminous Pro Series uses CE-registered Class 1 medical device transillumination patented technology. By…